Combining the Anti-EGFR Agent Gefitinib With Chemotherapy in Non–Small-Cell Lung Cancer: How Do We Go From INTACT to Impact?
- 1 March 2004
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (5) , 759-761
- https://doi.org/10.1200/jco.2004.12.903
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1Journal of Clinical Oncology, 2004
- Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2Journal of Clinical Oncology, 2004
- Of Looking Back and Looking ForwardJournal of Clinical Oncology, 2004
- O-244 Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens: Predicting response to gefitinib, an EGFR kinase inhibitorLung Cancer, 2003
- Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of CancerJournal of Clinical Oncology, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Influence of Unrecognized Molecular Heterogeneity on Randomized Clinical TrialsJournal of Clinical Oncology, 2002
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001